After tough year, Baxter looks for next CEO to drive growth

Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” to simplify the business structure.

By Susan Kelly • Feb. 21, 2025

Philips expects sales struggles in China to continue in 2025

Philips forecast a double-digit sales decline in China for the first half of 2025 after reporting “significant deterioration” of demand in October.

By Nick Paul Taylor • Feb. 19, 2025

Medtronic nears FDA submission for Hugo robot

CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by the end of March.

By Ricky Zipp • Feb. 18, 2025

Edwards predicts second-half lift from TAVR label expansion

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

By Susan Kelly • Feb. 12, 2025

Inspire Medical reveals DOJ civil investigation

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January for information on marketing and reimbursement practices.

By Ricky Zipp • Feb. 11, 2025

Mass General Brigham to conduct largest layoffs in its history

MGB said the layoffs were necessary to get ahead of an anticipated budget shortfall of $250 million over the next two years.

By Susanna Vogel • Feb. 11, 2025

M&A and a separation take center stage in latest earnings season

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 billion buy of Paragon 28.

By Susan Kelly • Feb. 10, 2025

Zimmer touts ASC opportunity with Paragon 28 purchase

With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace hips and knees.

By Elise Reuter • Feb. 6, 2025

Boston Scientific closes its year of PFA on a high note

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth quarter for the company’s electrophysiology group.

By Ricky Zipp • Feb. 5, 2025

23andMe considers sale as cash runs low

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.

By Nick Paul Taylor • Jan. 30, 2025

Getinge exits surgical perfusion, creating opportunity for Livanova

Getinge CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced the company off the U.S. market in 2015.

By Nick Paul Taylor • Jan. 30, 2025

Stryker to sell spinal implants business

The company named a new CFO and shared an update on its planned Inari Medical acquisition.

By Elise Reuter • Jan. 29, 2025

Intuitive execs cast wary eye on potential Trump tariffs

The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.

By Susan Kelly • Jan. 24, 2025

Abbott expects to launch first PFA device outside of the US this year

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

By Elise Reuter • Jan. 22, 2025

J&J coordinating with FDA on US pause of Varipulse due to safety risks

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will restart after halting procedures in early January.

By Ricky Zipp • Jan. 22, 2025

Trump’s return to office brings uncertainty for medtech industry

With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.

By Ricky Zipp • Dec. 18, 2024

Henry Schein to acquire medical supplier Acentus

Acentus, which specializes in supplying glucose sensors to patients’ homes, continues Henry Schein’s recent focus on building its homecare medical supplies business.

By Ricky Zipp • Nov. 21, 2024

Medtronic’s ablation sales slowed by PFA supply issues

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues that have now been resolved.

By Ricky Zipp • Nov. 19, 2024

Boston Scientific closes $3.7B Axonics deal after lengthy review

Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission requested more information.

By Ricky Zipp • Nov. 15, 2024

23andMe to lay off more than 200 employees amid business struggles

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”

By Ricky Zipp • Nov. 13, 2024

Baxter to restart second IV fluid production line at hurricane-damaged site

CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter from Hurricane Helene's disruption.

By Susan Kelly • Nov. 11, 2024

Exact Sciences’ forecast cut shocks analysts

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.

By Nick Paul Taylor • Nov. 8, 2024

Tandem, Insulet tout Type 2 expectations as tech attracts new users

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while Tandem plans to file a Type 2 submission by year’s end.

By Ricky Zipp • Nov. 8, 2024

Siemens Healthineers confident it can cope with Trump tariffs

CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump returns to the White House.

By Nick Paul Taylor • Nov. 7, 2024

Masimo, amid leadership transition, targets cost reductions

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not spun off.

By Susan Kelly • Nov. 6, 2024